New blood test may spot silica lung damage before symptoms appear

NCT ID NCT07376291

Not yet recruiting Diagnosis Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a specific antibody in the blood, called anti-CD146, can help doctors diagnose lung diseases caused by breathing in silica dust at work. Silica exposure can lead to serious lung problems like scarring, inflammation, and cancer, but there is currently no simple blood test to catch these diseases early. Researchers will compare 110 people with and without silica exposure to see if the antibody levels differ and relate to lung health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-CD146 autoantibodies (AACD146) as a blood biomarker
What this could lead to: If successful, this could lead to a simple blood test for early detection of silica-related lung diseases, allowing earlier treatment.
What could go wrong: This is an early-stage diagnostic study, not a treatment trial. The biomarker may not prove accurate enough for clinical use, and results may not apply to all exposed workers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXPOSURE OCCUPATIONAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXPOSURE OCCUPATIONAL PULMONARY DISEASES

More trials for these conditions

Other studies related to the condition(s) this trial covers.